Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gufic Biosciences's Other Operating Expense for the
three
months ended in Jun. 2026 was ₹1,069 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was ₹4,119 Mil.
Gufic Biosciences's quarterly Other Operating Expense
declined
from Dec. 2025 (₹1,051 Mil) to Mar. 2026 (₹973 Mil) but then
increased
from Mar. 2026 (₹973 Mil) to Jun. 2026 (₹1,069 Mil).
Gufic Biosciences's annual Other Operating Expense
increased
from Mar. 2024 (₹2,117 Mil) to Mar. 2025 (₹2,142 Mil) and
increased
from Mar. 2025 (₹2,142 Mil) to Mar. 2026 (₹2,143 Mil).
Gufic Biosciences Other Operating Expense Related Terms
Gufic Biosciences Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Gufic Biosciences's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4,119 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of ₹4,119 Mil mean?
Gufic Biosciences (BOM:509079) has a Other Operating Expense of ₹4,119 Mil as of Jun. 2026. Other operating expenses that a company records on its income statement. View historical data on Gufic Biosciences and its competitors.
Is Gufic Biosciences' Other Operating Expense too high?
Gufic Biosciences' current Other Operating Expense is ₹4,119 Mil. Overall, Gufic Biosciences has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gufic Biosciences' Other Operating Expense compare to ZTS?
Gufic Biosciences' Other Operating Expense of ₹4,119 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Gufic Biosciences and its competitors. Gufic Biosciences's current Other Operating Expense is ₹4,119 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gufic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Gufic Biosciences (BOM:509079) is currently considered Fairly Valued. The stock's GF Value™ is ₹425.56, compared to a current price of ₹432.90 — trading 1.7% above its estimated fair value. The current Other Operating Expense is ₹4,119 Mil. Gufic Biosciences' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Gufic Biosciences (BOM:509079), the current Other Operating Expense is ₹4,119 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gufic Biosciences (BOM:509079) Overvalued in 2026?
Based on GuruFocus' analysis, Gufic Biosciences stock appears to be overvalued.
The current stock price of ₹432.90 is trading 1.7% above its estimated GF Value™ of ₹425.56.
GuruFocus considers Gufic Biosciences to be Fairly Valued.
Key valuation signals for BOM:509079:
Other Operating Expense: ₹4,119 Mil
GF Value™: ₹425.56 vs. price of ₹432.90 (1.7% above fair value)
No single metric tells the full story. See the BOM:509079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare, Criticare Life, Ferticare, Spark, Herbal, and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral, and a proton-pump inhibitor. It derives maximum revenue from India.
73GF Score
Get the complete analysis for BOM:509079
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:509079 has been successfully added to your 
